Forty Seven, a GV-backed immuno-oncology spinout from Stanford University, has filed for a $115m initial public offering on Nasdaq just eight months after closing a $75m series B.

Forty Seven, a GV-backed immuno-oncology spinout from Stanford University, has filed for a $115m initial public offering on Nasdaq just eight months after closing a $75m series B.

Johnson & Johnson, Intermountain Healthcare and Nvidia have backed a $30m series C round for Zebra Medical Vision.

Pivotal BioVenture Partners and Roche have both returned to back a series C round for SutroVax, which has also added TPG, Medicxi and Foresite Capital to its shareholders.

BiomeSense won University of Chicago Innovation Fund's competition for its proposed biosensor that could provide medical feedback based on the bacteria found in a patient's faeces.

Camp4 has attracted capital from investors such as Kraft Group to continue development of its drug discovery platform based on work at MIT and Harvard Medical School.

Trajectory Next has received $125,000 in funding from Tedco to drive technologies including an ankle robot and voice-controlled heart disease management software.

Taikang Life and Lilly Asia Ventures, which backed the initial $59.7m series B round last year, have also contributed to a $35m series B+ round of Hangzhou Just Biotherapeutics.